Roche's Foun­da­tion Med­i­cine lays off 135 work­ers

Can­cer di­ag­nos­tics and ge­nom­ic pro­fil­er Foun­da­tion Med­i­cine is lay­ing off about 135 staffers, the com­pa­ny dis­closed ear­li­er this month.

The Roche sub­sidiary, val­ued at about $5.3 bil­lion when the Swiss Big Phar­ma ful­ly bought it out a few years ago, has liq­uid- and tis­sue-based biop­sy tests ap­proved by the FDA for var­i­ous sol­id tu­mors and works with bio­phar­ma part­ners on com­pan­ion di­ag­nos­tics for their clin­i­cal tri­als, in­clud­ing Bris­tol My­ers Squibb.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER